{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:15:26Z","timestamp":1780467326508,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00417-017-3834-3","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T04:17:40Z","timestamp":1510028260000},"page":"411-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy"],"prefix":"10.1007","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-6333","authenticated-orcid":false,"given":"Amir","family":"Mahdjoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Najean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Dendale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia Lumbroso-Le","family":"Rouic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"key":"3834_CR1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/eye.2012.126","volume":"26","author":"B Damato","year":"2012","unstructured":"Damato B (2012) Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond) 26:1157\u20131172. \nhttps:\/\/doi.org\/10.1038\/eye.2012.126","journal-title":"Eye (Lond)"},{"key":"3834_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/1740774511419684","volume":"8","author":"BS Hawkins","year":"2011","unstructured":"Hawkins BS (2011) Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin Trials 8:661\u2013673. \nhttps:\/\/doi.org\/10.1177\/1740774511419684","journal-title":"Clin Trials"},{"key":"3834_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000328257","volume":"49","author":"L Desjardins","year":"2012","unstructured":"Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C et al (2012) Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol 49:41\u201357. \nhttps:\/\/doi.org\/10.1159\/000328257","journal-title":"Dev Ophthalmol"},{"key":"3834_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/eye.2012.249","volume":"27","author":"C Groenewald","year":"2013","unstructured":"Groenewald C, Konstantinidis L, Damato B (2013) Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye (Lond) 27:163\u2013171. \nhttps:\/\/doi.org\/10.1038\/eye.2012.249","journal-title":"Eye (Lond)"},{"key":"3834_CR5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.ijrobp.2005.01.016","volume":"62","author":"B Damato","year":"2005","unstructured":"Damato B, Kacperek A, Chopra M et al (2005) Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys 62:1405\u20131411. \nhttps:\/\/doi.org\/10.1016\/j.ijrobp.2005.01.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3834_CR6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0360-3016(02)04200-1","volume":"55","author":"E Egger","year":"2003","unstructured":"Egger E, Zografos L, Schalenbourg A et al (2003) Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 55:867\u2013880","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3834_CR7","doi-asserted-by":"publisher","unstructured":"Seibel I, Riechardt AI, Heufelder J et al (2017) Adjuvant ab interno tumor treatment after proton beam irradiation. Am J Ophthalmol. \nhttps:\/\/doi.org\/10.1016\/j.ajo.2017.03.027","DOI":"10.1016\/j.ajo.2017.03.027"},{"key":"3834_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ijrobp.2006.01.020","volume":"65","author":"R Dendale","year":"2006","unstructured":"Dendale R, Lumbroso-Le Rouic L, Noel G et al (2006) Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys 65:780\u2013787. \nhttps:\/\/doi.org\/10.1016\/j.ijrobp.2006.01.020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3834_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1001\/archopht.124.6.838","volume":"124","author":"RM Conway","year":"2006","unstructured":"Conway RM, Poothullil AM, Daftari IK et al (2006) Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. Arch Ophthalmol 124:838\u2013843. \nhttps:\/\/doi.org\/10.1001\/archopht.124.6.838","journal-title":"Arch Ophthalmol"},{"key":"3834_CR10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/bjo.81.9.748","volume":"81","author":"A Foss","year":"1997","unstructured":"Foss A, Whelehan I, Hungerford J et al (1997) Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol 81:748\u2013754","journal-title":"Br J Ophthalmol"},{"key":"3834_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijrobp.2013.05.051","volume":"87","author":"KK Mishra","year":"2013","unstructured":"Mishra KK, Daftari IK, Weinberg V et al (2013) Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters. Int J Radiat Oncol Biol Phys 87:330\u2013336. \nhttps:\/\/doi.org\/10.1016\/j.ijrobp.2013.05.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3834_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/ICU.0000000000000239","volume":"27","author":"AA Aref","year":"2016","unstructured":"Aref AA (2016) Current management of glaucoma and vascular occlusive disease. Curr Opin Ophthalmol 27:140\u2013145. \nhttps:\/\/doi.org\/10.1097\/ICU.0000000000000239","journal-title":"Curr Opin Ophthalmol"},{"key":"3834_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/ICU.0000000000000141","volume":"26","author":"D Reichstein","year":"2015","unstructured":"Reichstein D (2015) Current treatments and preventive strategies for radiation retinopathy. Curr Opin Ophthalmol 26:157\u2013166. \nhttps:\/\/doi.org\/10.1097\/ICU.0000000000000141","journal-title":"Curr Opin Ophthalmol"},{"issue":"Pt 2","key":"3834_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/eye.1991.39","volume":"5","author":"DB Archer","year":"1991","unstructured":"Archer DB, Amoaku WM, Gardiner TA (1991) Radiation retinopathy--clinical, histopathological, ultrastructural and experimental correlations. Eye (Lond) 5(Pt 2):239\u2013251. \nhttps:\/\/doi.org\/10.1038\/eye.1991.39","journal-title":"Eye (Lond)"},{"key":"3834_CR15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/bjophthalmol-2013-304501","volume":"98","author":"L Konstantinidis","year":"2014","unstructured":"Konstantinidis L, Groenewald C, Coupland SE, Damato B (2014) Trans-scleral local resection of toxic choroidal melanoma after proton beam radiotherapy. Br J Ophthalmol 98:775\u2013779. \nhttps:\/\/doi.org\/10.1136\/bjophthalmol-2013-304501","journal-title":"Br J Ophthalmol"},{"key":"3834_CR16","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1167\/iovs.10-5526","volume":"51","author":"LV Ly","year":"2010","unstructured":"Ly LV, Bronkhorst IHG, van Beelen E et al (2010) Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci 51:5445\u20135451. \nhttps:\/\/doi.org\/10.1167\/iovs.10-5526","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3834_CR17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.86.4.448","volume":"86","author":"SR Boyd","year":"2002","unstructured":"Boyd SR, Tan D, Bunce C et al (2002) Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 86:448\u2013452","journal-title":"Br J Ophthalmol"},{"key":"3834_CR18","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/archopht.124.10.1428","volume":"124","author":"GSO Missotten","year":"2006","unstructured":"Missotten GSO, Notting IC, Schlingemann RO et al (2006) Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol 124:1428\u20131434. \nhttps:\/\/doi.org\/10.1001\/archopht.124.10.1428","journal-title":"Arch Ophthalmol"},{"key":"3834_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3892\/mco.2014.247","volume":"2","author":"M Yang","year":"2014","unstructured":"Yang M, Kuang X, Pan Y et al (2014) Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: a meta-analysis. Mol Clin Oncol 2:363\u2013368. \nhttps:\/\/doi.org\/10.3892\/mco.2014.247","journal-title":"Mol Clin Oncol"},{"key":"3834_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/sj.eye.6702072","volume":"20","author":"SR Boyd","year":"2006","unstructured":"Boyd SR, Gittos A, Richter M et al (2006) Proton beam therapy and iris neovascularisation in uveal melanoma. Eye (Lond) 20:832\u2013836. \nhttps:\/\/doi.org\/10.1038\/sj.eye.6702072","journal-title":"Eye (Lond)"},{"key":"3834_CR21","doi-asserted-by":"publisher","first-page":"323.e2","DOI":"10.1016\/j.ajo.2010.08.040","volume":"151","author":"BR Lima","year":"2011","unstructured":"Lima BR, Schoenfield LR, Singh AD (2011) The impact of intravitreal bevacizumab therapy on choroidal melanoma. Am J Ophthalmol 151:323.e2\u2013328.e2. \nhttps:\/\/doi.org\/10.1016\/j.ajo.2010.08.040","journal-title":"Am J Ophthalmol"},{"key":"3834_CR22","first-page":"2454","volume":"18","author":"M Filali el","year":"2012","unstructured":"el Filali M, Ly LV, Luyten GPM et al (2012) Bevacizumab and intraocular tumors: an intriguing paradox. Mol Vis 18:2454\u20132467","journal-title":"Mol Vis"},{"key":"3834_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ophtha.2013.08.039","volume":"121","author":"SU Shah","year":"2014","unstructured":"Shah SU, Shields CL, Bianciotto CG et al (2014) Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology 121:269\u2013275. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2013.08.039","journal-title":"Ophthalmology"},{"key":"3834_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12325-016-0461-z","volume":"34","author":"V Andr\u00e9s-Guerrero","year":"2017","unstructured":"Andr\u00e9s-Guerrero V, Perucho-Gonz\u00e1lez L, Garc\u00eda-Feijoo J et al (2017) Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma. Adv Ther 34:378\u2013395. \nhttps:\/\/doi.org\/10.1007\/s12325-016-0461-z","journal-title":"Adv Ther"},{"key":"3834_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3129\/i08-171","volume":"44","author":"LM V\u00e1squez","year":"2009","unstructured":"V\u00e1squez LM, Somani S, Altomare F, Simpson ER (2009) Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma. Can J Ophthalmol 44:106\u2013107. \nhttps:\/\/doi.org\/10.3129\/i08-171","journal-title":"Can J Ophthalmol"},{"key":"3834_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3129\/i09-259","volume":"45","author":"SN Yeung","year":"2010","unstructured":"Yeung SN, Paton KE, Waite C, Maberley DA (2010) Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma. Can J Ophthalmol 45:269\u2013273. \nhttps:\/\/doi.org\/10.3129\/i09-259","journal-title":"Can J Ophthalmol"},{"key":"3834_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000328633","volume":"47","author":"JP Caujolle","year":"2012","unstructured":"Caujolle JP, Maschi C, Freton A et al (2012) Treatment of neovascular glaucoma after proton therapy for uveal melanomas with ranibizumab injection: preliminary results. Ophthalmic Res 47:57\u201360","journal-title":"Ophthalmic Res"},{"key":"3834_CR28","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00417-016-3310-5","volume":"254","author":"AI Riechardt","year":"2016","unstructured":"Riechardt AI, Cordini D, Rehak M et al (2016) Trabeculectomy in patients with uveal melanoma after proton beam therapy. Graefes Arch Clin Exp Ophthalmol 254:1379\u20131385. \nhttps:\/\/doi.org\/10.1007\/s00417-016-3310-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3834_CR29","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archopht.1996.01100140299007","volume":"114","author":"JL Kinyoun","year":"1960","unstructured":"Kinyoun JL, Lawrence BS (1960) Barlow WE (1996) proliferative radiation retinopathy. Arch Ophthalmol 114:1097\u20131100","journal-title":"Arch Ophthalmol"},{"key":"3834_CR30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.ophtha.2009.10.015","volume":"117","author":"C Bianciotto","year":"2010","unstructured":"Bianciotto C, Shields CL, Pirondini C et al (2010) Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma. Ophthalmology 117:1005\u20131012. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2009.10.015","journal-title":"Ophthalmology"},{"key":"3834_CR31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0002-9394(02)02292-4","volume":"136","author":"DH Char","year":"2003","unstructured":"Char DH, Bove R, Phillips TL (2003) Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments. Am J Ophthalmol 136:180\u2013182","journal-title":"Am J Ophthalmol"},{"key":"3834_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000094834","volume":"38","author":"L Desjardins","year":"2006","unstructured":"Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C et al (2006) Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res 38:255\u2013260. \nhttps:\/\/doi.org\/10.1159\/000094834","journal-title":"Ophthalmic Res"},{"key":"3834_CR33","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1097\/IAE.0b013e31827f65c8","volume":"33","author":"N Cassoux","year":"2013","unstructured":"Cassoux N, Cayette S, Plancher C et al (2013) Choroidal melanoma: does endoresection prevent neovascular glaucoma in patient treated with proton beam irradiation? Retina 33:1441\u20131447. \nhttps:\/\/doi.org\/10.1097\/IAE.0b013e31827f65c8","journal-title":"Retina"},{"key":"3834_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1442-9071.2009.02127.x","volume":"37","author":"SK Gibran","year":"2009","unstructured":"Gibran SK, Kapoor KG (2009) Management of exudative retinal detachment in choroidal melanoma. Clin Experiment Ophthalmol 37:654\u2013659. \nhttps:\/\/doi.org\/10.1111\/j.1442-9071.2009.02127.x","journal-title":"Clin Experiment Ophthalmol"},{"key":"3834_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.5301\/EJO.2011.6477","volume":"21","author":"H Newman","year":"2011","unstructured":"Newman H, Finger PT, Chin KJ, Pavlick AC (2011) Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma. Eur J Ophthalmol 21:796\u2013801. \nhttps:\/\/doi.org\/10.5301\/EJO.2011.6477","journal-title":"Eur J Ophthalmol"},{"key":"3834_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ajo.2012.06.026","volume":"155","author":"R Parrozzani","year":"2013","unstructured":"Parrozzani R, Pilotto E, Dario A et al (2013) Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma. Am J Ophthalmol 155:127\u2013133.e2. \nhttps:\/\/doi.org\/10.1016\/j.ajo.2012.06.026","journal-title":"Am J Ophthalmol"},{"key":"3834_CR37","doi-asserted-by":"publisher","first-page":"693.e2","DOI":"10.1016\/j.ajo.2014.07.002","volume":"158","author":"I Mantel","year":"2014","unstructured":"Mantel I, Schalenbourg A, Bergin C et al (2014) Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma. Am J Ophthalmol 158:693.e2\u2013701.e2. \nhttps:\/\/doi.org\/10.1016\/j.ajo.2014.07.002","journal-title":"Am J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-017-3834-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T03:37:08Z","timestamp":1517283428000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-017-3834-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3834"],"URL":"https:\/\/doi.org\/10.1007\/s00417-017-3834-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]}}}